Cositecan

Drug Profile

Cositecan

Alternative Names: BNP 1350; BNP Karenitecin; DB 172; Karenitecin; UNII-24R60NVC41

Latest Information Update: 02 Nov 2015

Price : $50

At a glance

  • Originator BioNumerik Pharmaceuticals
  • Developer Alliance for Clinical Trials in Oncology; Baylor College of Medicine; BioNumerik Pharmaceuticals; Pediatric Brain Tumor Consortium
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Brain cancer; Malignant melanoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Sep 2015 BioNumerik is still developing the oral formulation of cositecan
  • 02 Sep 2015 BioNumerik is considering further development options for cositecan in Ovarian cancer (Mucinous disease, Late-stage disease)
  • 23 Mar 2012 BioNumerik Pharmaceuticals completes enrolment in its phase III trial for Ovarian cancer in Hungary, Lithuania, Poland, Romania and Russia (NCT00477282)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top